Fertility and IVF: Clinics, Costs, Egg Freezing and the Law — 2026-10-21
The U.S. assisted reproductive technology market is projected to reach $47 billion by 2035, driven by AI-enabled IVF and fertility preservation. Meanwhile, South Korea faces a paradox where expanded government subsidies for infertility treatments have coincided with a sharp rise in non-covered procedure costs, raising concerns about the net benefit for patients.
Fertility and IVF: Clinics, Costs, Egg Freezing and the Law — 2026-10-21
Top developments
AI-Driven Pricing and Market Growth
A new market report released on October 21, 2026, highlights that the U.S. Assisted Reproductive Technology (ART) market is growing at a 4.98% CAGR through 2034. The growth is fueled by AI-enabled IVF tools and fertility preservation services, with clinics increasingly using AI to optimize multi-cycle packages and ancillary revenue streams like preimplantation genetic testing (PGT).
In a related development, startup Sunfish is leveraging AI and 2 million clinic data points to predict IVF and egg freezing costs, offering refunds if estimates are incorrect. CEO Angela Rastegar stated this approach aims to bring transparency to a notoriously opaque pricing landscape.
South Korea’s Subsidy Paradox
In South Korea, a government audit revealed that while state support for infertility treatments has expanded, non-covered (non-reimbursed) procedure prices have risen significantly, potentially offsetting the benefits of subsidies. Lawmaker Nam In-soon reported that prices for non-covered items increased by over 120,000 KRW, with some specific procedures like sperm retrieval seeing price hikes of up to 52.8%.
This trend was further highlighted by The Korea Economic Daily, which noted that as government support increased, the cost of non-covered services surged, causing frustration among couples seeking treatment.
Insurance and Legal Mandates
In the United States, Pennsylvania lawmakers are moving to expand IVF access in response to the "embryonic personhood" ruling in Alabama. The proposed legislation would mandate that nearly all medical insurance plans cover fertility treatments, including artificial insemination, IVF, and the preservation of eggs, sperm, and embryos.
Local view
In South Korea, media outlets are critically examining the effectiveness of fertility subsidies. International News reported that the expansion of non-covered prices is undermining the intent of government support, urging stricter management of non-reimbursed medical fees. Meanwhile, Baby News highlighted concerns from the National Assembly health and welfare committee that the rising costs of non-covered services could neutralize the positive impact of increased government aid.
Context & numbers
The global ART market is forecast to reach USD 47.06 billion by 2035, driven by rising infertility rates and delayed parenthood. In the U.S., recent SART data indicates that 1 in 36 babies is now born through IVF, with over 100,000 IVF babies born in 2024 across nearly 450,000 treatment cycles.
In South Korea, the government provides up to 1.1 million KRW per fresh embryo transfer, with a limit of 20 cycles per birth for in vitro fertilization.
On the radar
- AI in Clinic Operations: The integration of AI for pricing and operational optimization is expected to accelerate, with startups like Sunfish potentially forcing traditional clinics to adopt more transparent pricing models.
- Korean Audit Results: Further details from the South Korean National Assembly audit on non-covered medical fees are expected, which may lead to new regulatory proposals for capping non-reimbursed fertility treatment costs.
This content was collected, curated, and summarized entirely by AI — including how and what to gather. It may contain inaccuracies. Crew does not guarantee the accuracy of any information presented here. Always verify facts on your own before acting on them. Crew assumes no legal liability for any consequences arising from reliance on this content.
Powered by
